GlassScriptPhysician profile
Kevin Lavender
NPI 1811450638
$4,143.93
in general payments reported to CMS, 2019-2025
25 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.70 · 2021: $109 · 2022: $341 · 2023: $1,673 · 2024: $1,033 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,675.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.05 | 2023-2025 | |
| Pfizer INC. | $565.24 | 2022-2025 | |
| Novo Nordisk INC | $555.25 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $550.36 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $351.40 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $288.58 | 2022-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.23 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $163.32 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $139.54 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.85 | 2023-2025 | Xifaxan |
| Exact Sciences Corporation | $84.60 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $56.16 | 2022 | |
| Merck Sharp & Dohme LLC | $50.10 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Ibsa Pharma INC. | $49.20 | 2023-2024 | Tirosint, Licart, Tirosint |
| Currax Pharmaceuticals LLC | $43.43 | 2023-2025 | Contrave |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $42.75 | 2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $32.59 | 2022-2023 | Gattex |
| Tolmar, INC. | $29.40 | 2023-2024 | |
| Inspire Medical Systems, INC. | $27.40 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $26.57 | 2022-2023 | Seglentis |
| Sanofi Pasteur INC. | $24.12 | 2023 | |
| Sumitomo Pharma America, INC. | $22.57 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $17.97 | 2023 | Keveyis |
| Bausch Health US, LLC | $16.93 | 2022 | |
| Antares Pharma, INC. | $13.32 | 2023 | Xyosted, Tlando, Nocdurna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lavender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.